Why the Incannex (ASX:IHL) share price is rocketing 170% in 2021

Investors are seemingly optimistic on the healthcare company.

| More on:
women working with medicinal marijuana, indicating a share price movement in ASX cannabis shares

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Incannex Healthcare Ltd (ASX: IHL) share price is having a year to remember.

At the time of writing, shares in the company are up 170% in 2021 and 3.7% today to 42 cents each. It's an impressive feat with many factors behind it.

Let's take a closer look and see why the company's shares are so high.

Company profile

Incannex is a pharmaceutical company that specialises in medicinal cannabinoid and psychedelic products. It sells worldwide, with a particular focus on the United States. The company, however, does not have regulatory approval to sell its products in the US.

The company claims its medicines can be used to treat a range of ailments, including anxiety, sleep apnoea, traumatic brain injury, respiratory illnesses such as asthma, arthritis, and inflammatory bowel disease.

Why the Incannex share price is blazing in 2021

The Incannex share price has been absolutely rocketing in 2021 — for a variety of reasons.

For example, in March, shares in the company leapt 10% on the news a clinical trial by the company proved its treatment to be more effective in treating rheumatoid arthritis than currently available medications.

The company's announcement at the time said the drug was up to 3.5 times more effective at reducing arthritis than common treatments currently on the market.

At present, the main treatment for rheumatoid arthritis is hydroxychloroquine (HCQ), marketed as Plaquenil. The company noted long term use of HCQ has been linked to increased cardiovascular mortality. HCQ has been in the news recently over debunked claims the drug could treat COVID-19.

Another reason for the rising Incannex share price is the company's ongoing process to navigate the regulatory framework of the world. In July, for example, Incannex filed a patent application for use in Europe, Japan, and Australia for its IHL-42X development program. Its share price increased on the news.

As well, in August, the Incannex share price rose 9% when the company announced it was taking the first steps to list American depository shares (ADS) on NASDAQ. 1 share of the ADS would be equivalent to 50 shares of Incannex on the ASX. Shareholders still need to approve of this decision.

Incannex FY21 results

For financial year 21, Incannex reported the following:

  • Revenue from ordinary activities up 214% to $1.9 million.
  • Losses for the year jumped 73.8% to $8.2 million.
  • Basic loss per share of 83 cents – up from a 69 cent per share loss in the prior corresponding period (pcp).
  • Net cash from operating activities outflow of $6.9 million which is higher than the $3.9 million outflow in the pcp.

The Incannex share price rose 7.79% on the day of the results announcement.

Incannex share price snapshot

Since listing on the ASX, the Incannex share price has fallen 91.3%. However, over 5 years, it is up 406% and over 12 months, it is 710% higher.

The company has a market capitalisation of around $453 million.

More on Cannabis Shares

A man in a horse head mask and suit jumps for joy on a beach.
Cannabis Shares

Could ASX cannabis shares be set for a smoking hot rebound?

ASX cannabis stocks could be set for a strong finish to 2024.

Read more »

Man in a cannabis greenhouse looks unhappy and puts his thumb down.
Cannabis Shares

Why are these 2 ASX cannabis stocks sputtering today?

Up 174% in 2023, this ASX cannabis share is giving back some more of its gains today.

Read more »

A young male investor wearing a white business shirt screams in frustration with his hands grasping his hair after ASX 200 shares fell rapidly today and appear to be heading into a stock market crash
Cannabis Shares

Guess which ASX cannabis share is crashing 36% following an FDA blow

Rookie mistake: This cannabis share just missed out on FDA approval for a simple reason.

Read more »

A Cronos Australia farmer and ASX cannabis shares investor stands in a field of cannabis plants and smiles at the camera
Cannabis Shares

Could ASX cannabis shares be set for a resurgence?

The world's legal and medical fraternities are taking small steps forward in the medicinal cannabis movement.

Read more »

A young woman holding her phone smiles broadly and looks excited, after receiving good news.
Cannabis Shares

This ASX cannabis stock is up 160% since June, and it has an FDA ruling coming up!

Investors are very excited about this cannabis stock.

Read more »

two men in formal business clothing closely inspect a bud from a cannabis crop.
Cannabis Shares

Why ASX cannabis shares just jumped back into the spotlight

ASX cannabis shares operate in a nation where medical marijuana is legal but recreational use remains broadly forbidden.

Read more »

A hip young man with a beard and manbun sits thoughtfully at his laptop computer in a darkened room, staring at the screen with his chin resting on his hand in thought.
Cannabis Shares

Should I buy Incannex shares while they're at multi-year lows, or steer clear?

Is the cannabis-based pharma company a bargain buy right now?

Read more »

Man in the green house growing medical cannabis
Cannabis Shares

A $3k investment in ASX cannabis stock Incannex 5 years ago is now worth $15,000. Here's why

This medicinal cannabis company has been a rare winner in its field.

Read more »